iMMagine-1 Trial: Data for Anito-Cel in R/R Myeloma After 3 Prior Lines of Therapy

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, review data from the phase 2 iMMagine-1 trial (NCT05396885) evaluating anitocabtagene autoleucel (anito-cel) in relapsed or refractory multiple myeloma after three prior lines of therapy. They discuss efficacy outcomes, safety observations, and depth of response reported in the study. Patel and Frigault place these findings in context of current CAR T-cell therapy benchmarks.